Crystal Research Releases Executive Overview of AtheroNova (AHRO)

AtheroNova (OTCBB: AHRO) is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention.

Crystal Research Associates has released an executive overview of the company. The report includes investment highlights, executive overview, corporate growth strategy, intellectual property, company leadership, core story (Atherosclerosis, AtheroNova's AHRO-001, Corporate Agreements), competition, milestones, historical financial results, risks, recent events, and glossary. 

See the full report below.  

Crystal Research AtheroNova Executive Overview June 2012

View more documents from DailyDoseEquities

AtheroNova Signs Agreement for Development of Clinical Trial Supplies ($AHRO)

AtheroNova (OTCBB: AHRO) is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits.  The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention.

AtheroNova announced it has signed an agreement with Frontage Laboratories, Inc. to commence analysis of their AHRO-001 compound and formulate a production plan in preparation for Phase I trials.  Frontage Laboratories, Inc., a leading pharmaceutical contract research organization, was chosen based on previous successful relationships with The Company. Work formulating and validating manufacturing procedures of manufacturing AHRO-001 tablets will begin immediately.

AtheroNova CEO Thomas W. Gardner commented,

"Frontage has been extremely diligent in dealing with the technical and physical requirements of our AHRO-001 compound and we look forward to commencing our project in the coming days.  We are very confident that Frontage will deliver a quality product in a timely manner. We continue to adhere to our vigorous development path and anticipate additional exciting development milestones in the coming months."

View the full press release here.  

AtheroNova ($AHRO) C.E.O. Thomas W. Gardner on atherosclerosis market size (video)

AtheroNova (OTCBB: AHRO) is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits.

In this film, AtheroNova C.E.O. Thomas W. Gardner speaks about the market size for atherosclerosis:

Watch more on Film Annex

ProActive Capital Resources Group Announces Client Participation at San Francisco Healthcare Conferences

JP Morgan's 30th Annual Healthcare Conference 

5^th Annual OneMedForum San Francisco 2012

Biotech Showcase 2012 in San Francisco

New York, NY, January 9, 2012 – ProActive Capital Resources Group, a strategic corporate communications, investor relations and social media firm today announced that several of its clients will be presenting at three prestigious investor conferences in San Francisco next week. The following companies will be presenting their corporate presentations at JP Morgan's 30th Annual Healthcare Conference, the 5^th Annual OneMedForum San Francisco 2012, and the Biotech Showcase 2012 in San Francisco.

“We are proud to have several of our clients presenting at these quality industry conferences as we continue to grow our healthcare practice at ProActive Capital,” stated Jeff Ramson, CEO of ProActive Capital Resources Group. “These healthcare conferences provide the visibility and help build awareness as our clients continue to execute on their growth initiatives.”

To schedule a one on one meeting with any of the companies please contact us at the number below.

Coronado Biosciences, Inc. (Nasdaq:CNDO), will present at the Biotech Showcase 2012 Conference on Wednesday, January 11, 2012 at 4:30 PM PT.

Ventrus BioSciences, Inc. (Nasdaq:VTUS) will be attending the conferences and is available for one on one meetings.

Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) will be presenting at JP Morgan's 30th Annual Healthcare Conference on Thursday, January 12, 2012 at 10:00 a.m. PT.

WaferGen Biosystems, Inc. (OTCBB:WGBS.OB) - The company is scheduled to present at OneMedForum on Tuesday, January 10, 2012 beginning at 10:00 a.m. PT.

Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP.OB), will be presenting at the Biotech Showcase 2012 on Monday, January 9, 2012 at 10:00 a.m. PT, as well as on Tuesday, January 10, 2012 at 10:15 a.m. PT at the OneMedForum Conference.

AtheroNova, (OTCQB: AHRO.OB) will be attending the conferences and is available for one on one meetings.

Fibrocell Science, Inc. (OTCBB:FCSC.OB), will be presenting at the 5^th Annual OneMedForum on Wednesday, January 11, 2012 at 10:00 a.m. PT.

Cerecor Inc. (a privately held company) will present at the Biotech Showcase 2012 on Monday, January 9th at 10:00 AM PST. 

NeoStem, Inc. (NYSE Amex: NBS) will be presenting at Biotech Showcase 2012 on January 10, 2012 at 10:30 a.m. PT.

CytoSorbents Corporation (OTC.BB: CTSO.OB), will present at the OneMedForum 2012 on Wednesday, January 11, 2012 at 11:15a.m. PT.

For more information about each of the conferences, go to:

www.onemedplace.com/forum/

http://www.ebdgroup.com/bts/index.php

About ProActive Capital Resources Group, LLC

ProActive Capital Resources Group, LLC (“PACRG”) (www.proactivecrg.com) is dedicated to the discovery and creation of value in the small-cap marketplace. PACRG provides turnkey solutions that combine traditional investor relations services with the latest Internet, mobile and social media communications. The Company’s integrated digital media and global distribution platform www.ProActiveNewsroom.com connects innovative, emerging-growth companies to the investment community using a variety of user-friendly and interactive formats.

Investor Relations Contact:

Jeff Ramson

Proactive Capital Resources Group, LLC.

212-792-4294

jramson@proactivecrg.com